Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

PTN Palatin Technologies Inc New

1,81

-0,01 (-0,55%)

Nach Börsenschluss

Zuletzt aktualisiert: 22:15:03

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

Palatin Technologies (AMEX:PTN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Palatin Technologies Charts.

Palatin Technologies (AMEX:PTN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Palatin Technologies Charts.

News Palatin Technologies Inc New

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
Freitag 21 Juni 2024 (4 Tage vor) • PR Newswire (US)

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
Donnerstag 20 Juni 2024 (5 Tage vor) • PR Newswire (US)

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Mittwoch 12 Juni 2024 (2 Wochen vor) • PR Newswire (US)

Form 8-K - Current report
Mittwoch 15 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 15 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Mittwoch 15 Mai 2024 (1 Monat vor) • PR Newswire (US)

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
Donnerstag 9 Mai 2024 (2 Monate vor) • PR Newswire (US)

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Donnerstag 2 Mai 2024 (2 Monate vor) • PR Newswire (US)

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Dienstag 30 April 2024 (2 Monate vor) • PR Newswire (US)

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Montag 8 April 2024 (3 Monate vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 7 März 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Montag 4 März 2024 (4 Monate vor) • Edgar (US Regulatory)

Weitere Palatin Technologies Inc New News-Artikel

Deutsche Telekom

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen